Gene stereotactic neurosurgery for recurrent malignant gliomas

Four patients affected by glioblastoma recurrence were treated with a gene therapy-immunotherapy protocol consisting of intratumoral injections of culture cells producing a retroviral vector which expresses human interleukin-2 and the herpes simplex virus thymidine kinase genes. Seven to 14 days after implantation, the patients were treated with ganciclovir at standard doses. Anatomopathological and immunohistochemical data confirm the efficacy of transduction. From the clinical point of view, gene therapy combined with immunotherapy demonstrated safety and a short-range but clearcut oncolytic effect.